Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype.

Vera JH, Naous N, Mackie N, Winston A, Cooke G.

AIDS. 2013 Jan 28;27(3):484-5. doi: 10.1097/QAD.0b013e32835a9a0d.

PMID:
23032409
2.

HLA-B*5701 and flucloxacillin associated drug-induced liver disease.

Phillips EJ, Mallal SA.

AIDS. 2013 Jan 28;27(3):491-2. doi: 10.1097/QAD.0b013e32835ca9d5. No abstract available.

PMID:
23291545
4.

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.

Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP; DILIGEN Study; International SAE Consortium.

Nat Genet. 2009 Jul;41(7):816-9. doi: 10.1038/ng.379. Epub 2009 May 31.

PMID:
19483685
5.

Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.

Kaniwa N, Saito Y.

J Hum Genet. 2013 Jun;58(6):317-26. doi: 10.1038/jhg.2013.37. Epub 2013 May 2. Review.

PMID:
23635947
6.

Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.

Guo Y, Shi L, Hong H, Su Z, Fuscoe J, Ning B.

Sci China Life Sci. 2013 Feb;56(2):119-24. doi: 10.1007/s11427-013-4438-8. Epub 2013 Feb 8. Review. Erratum in: Sci China Life Sci. 2013 Mar;56(3):292.

PMID:
23393027
7.

Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.

Moragas M, Belloso WH, Baquedano MS, Gutierrez MI, Bissio E, Larriba JM, Fay F, Aulicino P, Gurevich JM, Yaunguzian MF, Maldonado AC, Falistocco C, Sen L, Mangano A.

Tissue Antigens. 2015 Jul;86(1):28-31. doi: 10.1111/tan.12575. Epub 2015 Apr 29.

PMID:
25922880
8.

Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury.

Monshi MM, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, Alfirevic A, Cederbrant K, Daly AK, French N, Pirmohamed M, Park BK, Naisbitt DJ.

Hepatology. 2013 Feb;57(2):727-39. doi: 10.1002/hep.26077.

PMID:
22987284
9.

Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.

Munderi P, Snowden WB, Walker AS, Kityo C, Mosteller M, Kabuye G, Thoofer NK, Ssali F, Gilks CF, Hughes AR; DART Trial Team.

Trop Med Int Health. 2011 Feb;16(2):200-4. doi: 10.1111/j.1365-3156.2010.02688.x. Epub 2010 Nov 23.

10.

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT.

Lancet. 2002 Mar 2;359(9308):727-32.

PMID:
11888582
11.

Successful implementation of a national HLA-B*5701 genetic testing service in Canada.

Lalonde RG, Thomas R, Rachlis A, Gill MJ, Roger M, Angel JB, Smith G, Higgins N, Trottier B.

Tissue Antigens. 2010 Jan;75(1):12-8. doi: 10.1111/j.1399-0039.2009.01383.x. Epub 2009 Oct 15.

PMID:
19843279
12.

Genetic association studies in drug-induced liver injury.

Daly AK, Day CP.

Semin Liver Dis. 2009 Nov;29(4):400-11. doi: 10.1055/s-0029-1240009. Epub 2009 Oct 13. Review.

PMID:
19826974
13.

T cells infiltrate the liver and kill hepatocytes in HLA-B(∗)57:01-associated floxacillin-induced liver injury.

Wuillemin N, Terracciano L, Beltraminelli H, Schlapbach C, Fontana S, Krähenbühl S, Pichler WJ, Yerly D.

Am J Pathol. 2014 Jun;184(6):1677-82. doi: 10.1016/j.ajpath.2014.02.018. Epub 2014 Apr 13.

PMID:
24731753
14.

Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.

Crovella S, Biller L, Santos S, Salustiano A, Brandao L, Guimaraes R, Segat L, Lima Filho JL, Arraes LC.

Clinics (Sao Paulo). 2011;66(8):1485-8. No abstract available.

15.

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.

Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M.

Pharmacogenetics. 2004 Jun;14(6):335-42.

PMID:
15247625
16.

[Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].

Pérez Prior N, Rocher Milla A, Soler Company E, Flores Cid J, Sarria Chust B.

Farm Hosp. 2009 May-Jun;33(3):155-60. Spanish.

PMID:
19712599
17.

Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects.

Orkin C, Sadiq ST, Rice L, Jackson F; UK EPI team.

HIV Med. 2010 Mar;11(3):187-92. doi: 10.1111/j.1468-1293.2009.00762.x. Epub 2009 Sep 24.

18.

Abacavir hypersensitivity reaction: an update.

Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, Lechelt KE.

Ann Pharmacother. 2008 Mar;42(3):387-96. doi: 10.1345/aph.1K522. Epub 2008 Feb 26. Review.

PMID:
18303141
19.

HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.

Poggi H, Vera A, Lagos M, Solari S, Rodríguez P L, Pérez CM.

Braz J Infect Dis. 2010 Sep-Oct;14(5):510-2.

20.

Genetics and the potential for predictive tests in adverse drug reactions.

Pirmohamed M.

Chem Immunol Allergy. 2012;97:18-31. doi: 10.1159/000335613. Epub 2012 May 3.

PMID:
22613851

Supplemental Content

Support Center